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ABSTRACT Computational methods designed to predict and visualize ligand protein binding interactions were used to
characterize volatile anesthetic (VA) binding sites and unoccupied pockets within the known structures of VAs bound to serum
albumin, luciferase, and apoferritin. We found that both the number of protein atoms and methyl hydrogen, which are within;8 A˚
of a potential ligand binding site, are signiﬁcantly greater in protein pockets where VAs bind. This computational approach was
applied to structures of calmodulin (CaM), which have not been determined in complex with a VA. It predicted that VAs bind to
[Ca21]4-CaM, but not to apo-CaM, which we conﬁrmed with isothermal titration calorimetry. The VA binding sites predicted for
the structures of [Ca21]4-CaM are located in hydrophobic pockets that form when the Ca
21 binding sites in CaM are saturated.
The binding of VAs to these hydrophobic pockets is supported by evidence that halothane predominantly makes contact with
aliphatic resonances in [Ca21]4-CaM (nuclear Overhauser effect) and increases the Ca
21 afﬁnity of CaM (ﬂuorescence
spectroscopy). Our computational analysis and experiments indicate that binding of VA to proteins is consistent with the
hydrophobic effect and the Meyer-Overton rule.
INTRODUCTION
Volatile anesthetics (VA) are small hydrophobic molecules
used to induce general anesthesia. A thorough understanding
of the mechanisms by which these drugs induce anesthetic
effects remains elusive, especially at the cellular level. Thus,
continued study of the molecular mechanisms of anesthetic
effects is warranted.
VAs interact with many cellular components, yet anes-
thetic effects ultimately manifest as changes in protein func-
tion. VAs have been shown to accumulate at the aqueous
interface of a dipalmitoylphosphatidylcholine membrane (1)
and at the protein-lipid interface region near the surface of
purple membrane (2). VAs are known to bind to transmem-
brane proteins such as the plasma membrane Ca21-ATPase
(3), rhodopsin (4), the nicotinic acetylcholine receptor (5,6),
and several proteins from rat neuronal membranes, assayed
in vitro (7). VAs also alter the function of several membrane-
delimited proteins such as the G-protein-coupled muscarinic
receptor complex (8) and the Ca21-ATPase pump (9). How-
ever, a lipid environment is not essential for anesthetic-
protein interactions. VAs are known to bind to soluble
proteins such as serum albumin (10), apoferritin (11), odor-
ant binding protein (12), ﬁreﬂy luciferase (13), and calmodu-
lin (14). VAs have been shown to inhibit the normal function
of luciferase (15) and such soluble mammalian proteins as
Protein kinase C (16–18) and multiple isoforms of G-protein
alpha subunits (19), which may be relevant to the anesthetic
mechanism. Together, these ﬁndings suggest that proteins
are potential molecular targets of anesthetics.
Protein structure affects the afﬁnity and stoichiometry
with which VAs bind. VAs bind to some proteins, such as
apoferritin (11), serum albumin (10), and odorant binding
protein (12), with dissociation constants (Kd) of;1 mM and
above, yet do not bind to other proteins even when present
at 10-fold higher concentrations (unpublished observations).
This suggests that VAs, when present at mM concentrations,
bind to some, but not all proteins. This was also observed in
the cellular environment, when the binding of VAs to pro-
teins from rat neuronal membranes was assayed in vitro (7).
In addition, this work suggests that VA binding to proteins in
the cellular environment is affected by protein conformation.
Conformational dependent binding of VAs to proteins has
also been observed using puriﬁed, isolated proteins. It has
been shown that VAs bind to apomyoglobin, but not myo-
globin (14,20) and Ca21-saturated calmodulin, but not
Ca21-free calmodulin (14). This suggests that VAs bind prefer-
entially to certain protein conformations. In some proteins,
such as serum albumin, some binding interactions are sat-
urable at VA concentrations achievable in aqueous environ-
ments (21). VA binding has also been shown to compete
with native ligands of some proteins, such as fatty acid bind-
ing to serum albumin (21,22) and the binding of the ﬁreﬂy
luciferase substrate luciferin (23). Thus, these ﬁndings in-
dicate that VAs bind to some, but not all proteins. VAs bind
preferentially to certain protein conformations, and VAs are
able to compete with certain protein ligands. Together, this
suggests that VAs bind speciﬁcally to structures within
certain proteins and protein assemblies.
High resolution structures of VAprotein complexes formed
between bromoformluciferase (13), halothanehuman serum
albumin (22), and halothaneapoferritin and isoﬂurane
apoferritin (11) were determined by other groups. In these
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works, it was found that VAs bind to preexisting pockets
lined with polar and apolar residues, which exist within
protein monomers and between oligomeric protein com-
plexes; binding was consistent with the hydrophobic effect,
yet the halogen atoms of the VAs may have weak polar
interactions with the protein, and the bound anesthetics in-
duced minor changes in protein structure. Thus, the struc-
tures of complexes formed between VAs and proteins, which
themselves are not physiologically relevant anesthetic tar-
gets, provide detailed information about the molecular inter-
actions and protein motifs that inﬂuence the binding of VAs
to proteins in general.
The main goal of this work is to correlate VA binding with
protein structure. Our use of computational tools, which are
designed to predict and visualize ligand binding pockets in
protein structures, is a novel aspect to this investigation. This
approach is applied to calmodulin (CaM), the structure of
which has not been determined in complex with VAs, and
empirical evidence supporting the predictions is provided.
CaM was studied because both the apo- and [Ca21]4-CaM
structures (24–26) can be utilized to investigate the structure-
dependent speciﬁcity for VA binding, which is inferred from
NMR experiments (14).
METHODS
CaM expression, enrichment, and puriﬁcation
Human calmodulin cDNA was subcloned into pET-15b expression vector
(Novagen, San Diego, CA) using standard cloning techniques. No pu-
riﬁcation tag was introduced into the construct. The identity of the insert was
conﬁrmed by DNA sequencing. CaM was overexpressed in BL21(DE3)-
pLysS strain of Escherichia coli (Single Shot, Novagen, San Diego, CA).
Uniform 13C, 15N enrichment was achieved by growing cells in Luria-
Bertani medium and then inducing in minimal media containing 13C-glucose
and 15NH4Cl following established protocols (27). Isotopically labeled and
unlabeled CaM were puriﬁed using a slight modiﬁcation to an existing
procedure (28). Five mM CaCl2 was added to the cleared cell lysate, which
was loaded onto a phenyl-Sepharose CL-4B column (Sigma, St. Louis,
MO), and the CaM was eluted with 1 mM EGTA. CaM fractions were
further puriﬁed using a HiTrap Q column (Amersham Biosciences, Uppsala,
Sweden) and a 0–1 M NaCl gradient. CaM was .95% pure, judging by
SDS-gel electrophoresis and Coomassie Brilliant-Blue staining. The identity
of the CaM was conﬁrmed by N-terminal sequencing as well as by LC-MS
analysis of the tryptic digests of labeled and unlabeled CaM. The molecular
weight and labeling efﬁciency (96%) were veriﬁed with ESI-MS by direct
infusion.
Isothermal titration calorimetry
Isothermal titration calorimetry (ITC) was used to estimate the thermody-
namic parameters (stoichiometry (n), dissociation constant (Kd), and en-
thalpy (DH)) of halothane [Ca21]4–CaM binding. We were concerned that it
would be difﬁcult to determine these parameters for VA-protein interactions
from a single ITC experiment because it might require very high protein
concentrations (29). Therefore, the binding isotherms were measured for
several concentrations of protein and the n, Kd, and DH determined as
parameters from a global ﬁt to the set of binding isotherms (30). In the
experiments, the heat associated with a series of 10 mL injections (30 total)
of a near-saturated solution of halothane (quantiﬁed by gas chromatography
(31)) into a solution of various concentrations of calmodulin dissolved in the
same buffer were measured using a VP-ITC microcalorimeter (Microcal,
Northampton, MA). The heats associated with diluting the protein and
halothane were measured in separate experiments by injecting buffer into the
cell-containing protein and by injecting halothane into the cell-containing
buffer, respectively. These heats were subtracted from the heat of
halothaneprotein binding. Measurements of halothane[Ca21]4–CaM bind-
ing were performed in 100 mM KCl and 6.2 mM CaCl2 (pH 7) and the
measurement of halothaneapoCaM binding was performed in 100 mMKCl,
1 mM EDTA, and 1 mM EGTA (pH 7). The binding isotherms were con-
structed by plotting the integrated heat versus the halothane: protein mole
ratio for ﬁve concentrations of CaM from 0.01 to 0.69 mM. The binding
isotherms were ﬁt to a single site model (32), which allowed for more than
one halothane binding site in the protein, but assumed that all sites had
equivalent Kd. We tested this approach using BSA and estimated that
halothane binds with a stoichiometry of 3, an apparent Kd of 1.8 mM, and a
DH ¼ 4.0 Kcal/mol (data not shown). These results are consistent with
values for VA binding to serum albumin determined by others using ITC,
NMR, and ﬂuorescence techniques (10,33,34). This ﬁnding suggests that
this approach could provide a reasonable estimate of n, Kd, and DH for
halothane binding to CaM.
CaM Ca21 Kd values
The Kd values of the Ca
21 binding sites of CaMwere determined using ﬂuo-
rescence spectroscopy. The intrinsic Tyr ﬂuorescence (excitation 277 nm,
emission 320 nm) increases threefold when Ca21 saturates the two Ca21
binding sites of the C-domain (35). Tyr residues in the C-domain can be used
to monitor the Ca21 binding to the C-domain sites without interference from
Phe residues in the N-domain ((35) and references therein). The intrinsic
phenylalanine ﬂuorescence (excitation 250 nm, emission 280 nm) decreases
by;30% when Ca21 saturates the two Ca21 binding sites on the N-domain
(36). At these excitation and emission frequencies, the Phe residues in the
N-domain report exclusively on the Ca21 occupancy of N-domain sites.
There is no contribution to the signal from the Phe residues in the C-domain,
no spectral interference from the Tyr residues in the C-domain, and no
observable energy transfer from the Phe residues in the N-domain to the Tyr
residues in the C-domain (35). Samples of 5 mM CaM in 50 mM MOPS
(pH 7.2), 100 mM KCl, 5 mM nitriloacetic acid, and 50 mM EGTA were
prepared in quartz cells sealed with Teﬂon stoppers, and stirred with Teﬂon-
coated micro stir bars. Small aliquots of a calcium stock solution were added
with a syringe through a port in the Teﬂon stopper. After each addition,
the solution was stirred for 2 min and the ﬂuorescence was recorded using
a thermostatically controlled Spex Fluoromax ﬂuorometer (Jobin Yvon,
Edison, NJ) with the slits set to 2 nm bandpass. Free Ca21 in the ﬂuo-
rescence titrations was determined with the ﬂuorescent probe Oregon Green
488 BAPTA-5N (Molecular Probes, Eugene, OR), which was calibrated
using standardized Ca21 solutions (Molecular Probes). Immediately after
the titration, an aliquot of the solution was removed for halothane con-
centration determination by gas chromatography (31). The normalized
ﬂuorescence change F ¼ (Fi-Fmin)/(Fmax-Fmin) for the tyrosine and phe-
nylalanine residues were plotted as a function of free Ca21 concentration
and ﬁt with the following equation (37):
F ¼ ½Ca
21 n
½Ca21 n1Knd
: (1)
Kd is the dissociation constant, [Ca
21] is the free Ca21 concentration, and n
is the Hill coefﬁcient. Each titration was performed in triplicate and each
titration curve was ﬁt to Eq. 1. The curve-ﬁt parameters for each set of
triplicate experiments were expressed as mean 6 SD in Table 3.
Halothane is a poor quencher of Tyr and Phe emission in CaM (Tyr, 5%
and Phe , 15% at 2.5 mM). The quenching of the emission was not
corrected because each titration was performed at constant halothane
concentrations and the degree of quenching was the same for apo- and
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[Ca21]4-CaM conformations (data not shown). The magnitude of the
changes in the Phe and Tyr emission intensities between apo- and [Ca21]4-
CaM were also insensitive to halothane concentrations up to 2.5 mM (data
not shown). This suggests the experimental conditions do not create a
signiﬁcant amount of chlorotriﬂuoroethy radical (38) or that any chlorotri-
ﬂuoroethy radical that cross-links with CaM does not affect the emission
intensities of Phe or Tyr and hence the assay.
NMR spectroscopy
The NOESY spectrum (39) of 2 mM CaM in 25 mM HEPES (pH 7.5),
100 mM KCl, 20 mM Ca21, 5 mM Mg21, 1 mM EDTA, and 4 mM
halothane was recorded at 298 K and a mixing time of 300 ms using a
600 MHz spectrometer equipped with a cryoprobe (Bruker, Billerica, MA).
Characterization and prediction of VA
binding sites
High resolution structures of VAprotein complexes deposited in the Protein
Data Bank (40) were analyzed for protein motifs that inﬂuenced VA binding.
The protein structures were HSA (1E7C (22)), luciferase (1BA3 (13)), and
the apoferritin dimer (chains B and E from 1IES (41)). The coordinates of
the bound VAs around HSAwere determined from a composite of 1E7B and
1E7C (22); around luciferase from 1BA3 (13); and around apoferritin from
1XZ3 (11). Visual molecular dynamics (VMD) (42) and associated pro-
grams were used to add hydrogen atoms to the proteins and solvate them in a
box of water at least 10 A˚ larger than the protein in all directions. NAMD
(43) was used to minimize the solvated protein structures.
The program Putative Active Sites with Spheres (PASS) (44) was used
to deﬁne VA binding site predictions (BSPs) for the minimized protein
structures. PASS is designed to predict the site(s) in protein structures where
small hydrophobic molecules prefer to bind. The PASS algorithm ﬁlls
pockets in protein structures with virtual probe spheres, which are assigned
a burial count (BC) equal to the number of protein atoms within 8 A˚. The
probe weight of the ith sphere (PWi) is calculated (Eq. 2) as the sum of the
burial counts of all spheres, which are scaled by an envelope function:
PWi ¼ +
Nprobes
j¼1
BCj3 e
ðrij2Þ2 : (2)
The envelope function attenuates the burial count of the jth sphere using a
function of its distance from the ith sphere (rij). The envelope function is
equal to 1 when rij # 2 A˚ and decays exponentially to 0 when rij $ 4.5 A˚.
Thus BC of spheres.;4.5 A˚ from the ith sphere contribute little to PWi. PW
is a measure of the hydrophobicity of the region surrounding the BSP even
though it is a function of all nearby protein atoms, regardless of whether
they are constituents of polar or nonpolar residues/functional groups. The
rationale is that the deeper a pocket is buried in the protein, the more hy-
drophobic it is likely to be. Thus, the structure of the protein pocket is
reduced to a number (PW), which PASS uses to rank the hydrophobicity of
the BSP. Note that PW is an absolute scale on which all proteins can be
compared. The probe with the largest PW (most buried) is the initial BSP
deﬁned for a protein structure. Subsequent BSPs are deﬁned in order of
decreasing PW using those probes, which are not within 8 A˚ of a prior BSP.
We modiﬁed the PASS algorithm to also calculate methyl burial counts,
which are equal to the number of methyl hydrogen atoms within 8 A˚ of
the probe, and methyl probe weights (PWMs), which were calculated by
substituting the methyl burial counts for BC in Eq. 2. This way we can
directly compare PW and PWM, because they have the same dimensions. All
methyl hydrogen atoms were taken into account: Ala (Hb), Val (Hg), Leu
(Hd), Ile (Hg2 and Hd), Met (He), and Thr (Hg2). The modiﬁed PASS al-
gorithm deﬁned the initial BSP as the probe with the largest PWM for a
protein structure. Subsequent BSPs are deﬁned in order of decreasing PWM
using those probes, which are not within 8 A˚ of a prior BSP. We iteratively
deﬁne BSPs in this way until all probes are exhausted. The coordinates
of BSPs were similar, whether they were ranked by PW (PASS) or PWM
(modiﬁed PASS), because the two values are interdependent. The BSPs
determined by the modiﬁed PASS along with the associated PW and PWM
values were used in the subsequent work.
BSPs were categorized as occupied if they were within 3 A˚ of a VA
molecule in the crystal structure of the VAprotein complex, fatty-acid-
displaceable if they were within 3 A˚ of a myristate ligand in the structure of
the HSAhalothane complex, or unoccupied if they were .3 A˚ from either.
The halothaneHSA structures were determined under two different con-
ditions. For 1E7B, an HSA crystal was exposed to 2.5 mM halothane and for
1E7C, an HSAmyristate crystal was exposed to 10 mM halothane. The
myristate ligands in 1E7C might be obscuring sites that would otherwise be
occupied by VAs. Rather than categorize them as unoccupied, they are
categorized as fatty-acid-displaceable.
We used VMD and a probe radius of 1.4 A˚ to calculate the solvent-
accessible surface area (SASA) of the aliphatic (Gly, Ala, Val, Leu, Ile, and
Pro), aromatic (Phe, Tyr, and Trp), sulfur-containing (Met and Cys), alcohol
(Ser and Thr), acidic (Asp and Glu), basic (His, Lys, and Arg), and amide
(Asn and Gln) residue types within 8 A˚ of the BSPs. In addition, we calcu-
lated the SASA of those residues containing at least one methyl functional
group (Ala, Val, Leu, Ile, Met, Thr) within 8 A˚ of the BSPs.
Prediction of VA binding sites in CaM
BSPs were deﬁned for the structures of apoCaM (1QX5, (24)), [Ca21]4–
CaM in extended conformation (1CLL (25)), and [Ca21]4-CaM in compact
conformation (1PRW (26)). BSPs in the CaM structures with PW and PWM
that exceeded the corresponding mean values of PW and PWM of the
unoccupied sites in the structures of VAprotein complexes by .61.5 SD,
were considered to be potential VA binding sites.
Statistics
Data are presented as mean6 SD. Signiﬁcance was determined by unpaired
t-test.
RESULTS
Volatile anesthetics bind to speciﬁc pockets
in proteins
There are a total of eight halothane found in the halothane
HSA structures. Of the 60 BSPs for HSA, six are occupied
by one or more VAs and seven are fatty-acid-displaceable.
There are two bromoforms observed in the bromoform
luciferase structure, and of the 33 BSPs for luciferase, two
are occupied. There is a single isoﬂurane in the isoﬂurane
apoferritin structure, which occupies one of the 24 BSPs for
the apoferritin dimer.
The mean SASAs calculated for various residue types
within 8 A˚ of the BSPs are listed in Table 1. The SASAs of
aliphatic residues and residues containing at least one methyl
functional group were signiﬁcantly greater around occupied
BSPs compared to unoccupied BSPs. There was not a sig-
niﬁcant difference between the SASAs of other residue types
around occupied versus unoccupied BSPs.
The mean values of PW and PWM for all BSPs are
tabulated according to category (Table 2) and are signiﬁ-
cantly greater for occupied than unoccupied BSPs. The two
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data sets were partially resolved using a scatter plot of their
PW and PWM (Fig. 1 A).
BSPs are deﬁned for the structures of apoCaM and both
extended and compact conformations of [Ca21]4-CaM. The
BSPs deﬁned for the apoCaM structure had PW and PWM
values characteristic of unoccupied sites whereas some BSPs
deﬁned for the [Ca21]4-CaM structures had PW and PWM
values characteristic of an occupied site (Fig. 1 B). The BSPs
with PW and PWM values characteristic of an occupied site
are all located within the hydrophobic pockets used in target
recognition and binding in the [Ca21]4-CaM structures
(Fig. 2).
Volatile anesthetics bind to hydrophobic sites in
[Ca21]4-CaM, but not apoCaM
Isothermal titration calorimetry (ITC) was used to conﬁrm
that halothane binds to [Ca21]4-CaM, but not apoCaM
(Fig. 3) and to estimate that halothane binds to [Ca21]4-CaM
with n of 1.5, Kd of 1.1 mM, DH of 4200 cal mol1, and a
DS of0.5 cal mol1 K1 (Fig. 4). Halothane concentrations
exceeding the Kd were used in all experiments to optimize
the occupation of the binding site(s).
The Ca21-dependence of intrinsic CaM ﬂuorescence was
used to show that 2.5 mM halothane signiﬁcantly decreases
the Ca21 Kd of the N-domain Ca
21 binding sites of CaM
from 7.4 to 5.1 mM and the C-domain Ca21 binding sites
from 1.5 to 0.77 mM (Fig. 5 and Table 3).
Multiple 1H resonances of [Ca21]4-CaM are observed
predominantly between 0 and 3 ppm and to a lesser extent
between 6 and 8 ppm in the one-dimensional slice from a
NOESY spectrum taken at the halothane 1H resonance fre-
quency of 6.3 ppm (Fig. 6).
DISCUSSION
The main ﬁnding of this work is that VAs occupy pockets
with signiﬁcantly larger PW and PWM than other potential
binding sites in the structures of HSA, luciferase, and
apoferritin. PW and PWM are quantitative descriptors of the
components of protein structure that inﬂuence VA binding.
Using these descriptors, it is possible to compare the diverse
structures of VA binding sites observed in the various VA
protein complexes using a common scale. These descriptors
TABLE 1 Solvent-accessible surface areas (mean 6 SD)
of various residue types around unoccupied, occupied,
and fatty-acid-displaceable BSPs
Residue type Unoccupied (100) Occupied (9)
Fatty acid
displaceable (7)
Aliphatic* 440 6 210 760 6 110 780 6 120
Containing CH3* 420 6 200 740 6 120 760 6 70
Aromatic 190 6 170 180 6 190 360 6 240
Containing sulfur 50 6 100 0 6 0 80 6 110
Alcohols 140 6 150 150 6 150 60 6 110
Acids 240 6 180 180 6 240 60 6 110
Bases 350 6 160 400 6 160 270 6 110
Amides 130 6 160 60 6 110 40 6 110
The number of BSPs in each category is given in parentheses and the areas
are expressed in units of A˚2.
*Signiﬁcant difference (p , 0.01) between occupied and unoccupied.
TABLE 2 BSP weights (mean6 SD) calculated for unoccupied,
occupied, and fatty-acid-displaceable BSPs
Weights Unoccupied Occupied
Fatty acid
displaceable
PW* 800 6 400 2000 6 300 1500 6 300
PWM* 200 6 100 700 6 200 600 6 200
The number of BSPs in each category is the same as in Table 1.
*Signiﬁcant difference (p , 0.01) between occupied and unoccupied.
FIGURE 1 Scatter plots of BSPs. (A) Scatter plot of the occupied, un-
occupied, and fatty-acid-displaceable BSPs. (B) Scatter plot of the BSPs for
apoCaM and extended and compact [Ca21]4-CaM. The axes in both plots
are drawn to the same scale.
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can be used to predict the site(s) of VA binding in protein
structures, which could be a powerful tool for the study of
molecular mechanisms of anesthesia.
Examination of the residues surrounding the BSPs in-
dicated that the mean SASAs of aliphatic residues and those
residues containing methyl groups were signiﬁcantly greater
for occupied BSPs compared to unoccupied BSPs (Table 1).
The signiﬁcance was approximately equivalent for either the
aliphatic residues or the residues containing methyl groups.
This suggests that the number of methyl groups around the
BSP can be used as an indicator of VA binding. On the other
hand, we did not ﬁnd any correlation between BSP occu-
pancy and the SASA of any other polar or apolar residue
types. Thus we could not discern any other indicators of VA
binding from this data set. Together, this suggests that the
hydrophobicity of the pocket around the BSP has greater
inﬂuence over the binding of VAs than the aromaticity or
polarity of the pocket. Others have also suggested that the
binding of VAs to protein targets is determined primarily by
hydrophobic and van der Waals forces (45). However, there
are too few structures to rule out the inﬂuences of aromatic or
polar residues or the effect of pocket geometry and orien-
tation on VA binding. Additional structures of VAprotein
complexes are needed to reﬁne this method because VAs
may bind to other members of the proteome through in-
teractions and at sites signiﬁcantly different than observed in
these complexes.
VA binding sites are partially resolved from unoccupied
pockets using a scatter plot of PW and PWM (Fig. 1). In the
scatter plot, the ordinate and abscissa axes bisect the means
of the occupied and unoccupied data, such that they are
spaced at equivalent standard deviation intervals from both
means (;61.5 SD). The occupied BSPs are predominantly
located in quadrant I (quadrants are numbered counterclock-
wise, starting from upper right). The exception to this is the
occupied BSP corresponding to the bromoform molecule
that binds to ﬁreﬂy luciferase through mainly polar interac-
tions (13), which is located in quadrant IV. Unoccupied
BSPs are found predominantly in quadrant III. The fatty-
acid-displaceable BSPs deﬁned for HSA could not be cat-
egorized as occupied or unoccupied, so their PW and PWM
values were excluded from the statistical analysis. They are
predominantly found in quadrants I and II. It has been shown
that fatty acids inhibit some VA binding to serum albumin
(21), so it is possible that VAs also bind to some of these
sites. Thus VA binding sites in the structures of VAprotein
complexes, including those that might be obscured by fatty
acids in HSA, correlate with the PW and PWM.
FIGURE 3 Titration of 100 mM apoCaM (left) and 100 mM [Ca21]4-CaM
(right) with halothane. The upper panels show the baseline-corrected data
for the injection of halothane into buffer (top trace), the injection of buffer
into calmodulin (middle trace), and the injection of halothane into calmod-
ulin (bottom trace). The bottom panels show the normalized heat changes for
each injection in calories per mole of halothane added, which were corrected
for the enthalpies of dilution of halothane and calmodulin. The dilutions of
halothane and [Ca21]4-CaM (upper right panel) were collected with a
shorter interval between injections than the titration of [Ca21]4-CaM with
halothane, which did not affect the subtraction of dilution enthalpies.
FIGURE 2 CaM structures used to determine BSPs. For clarity, the
N-terminal domain (up to residue 65) is blue, the linker region (residues 66–
92) is orange and the C-terminal domain (residues 93 and above) is green in
each representation. (Upper left) No BSPs in the occupancy range were
determined for apoCaM. (Lower left) A single BSP in the occupancy range
(solid black sphere) was determined for [Ca21]4-CaM in the compact
conformation. The methyl hydrogen atoms within 8 A˚ of the BSP are
represented as white spheres. All other atoms within 8 A˚ of the BSP are
represented with a transparent red surface so they do not obscure the methyl
hydrogens and BSP. (Right) Two BSPs in the occupancy range were
determined for [Ca21]4-CaM in the extended conformation. The BSPs are
represented as for compact [Ca21]4-CaM, except that the non-methyl
hydrogen atoms within 8 A˚ of the BSP in the C-terminal domain are rep-
resented with a solid red surface to show the surface features of the pocket.
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PW is proportional to the number of nearby protein atoms
and hence the exclusion of the binding site from the bulk
solvent. The mean PW of the occupied BSPs was more than
twice that of the unoccupied BSPs. This suggests that
VAprotein complex formation is promoted by the desolva-
tion of the VA (hydrophobic effect). However, the exother-
mic VA protein binding observed with titration calorimetry
(Fig. 3 and in (12,29,46)) indicates that it is not the only force
driving VA protein binding.
PWM is proportional to the number of nearby methyl
hydrogen and thus is related to the hydrophobicity of the
binding site. The mean PWM of occupied BSPs was more
than threefold greater than that of the unoccupied BSPs. The
preference of VAs for domains rich in methyl groups is
consistent with NMR experiments, which demonstrate that
halothane contacts predominantly aliphatic and aromatic
residues in HSA (47) and the VA methoxyﬂurane exclu-
sively contacts the choline methyl group in dipalmitoyl-
phosphatidylcholine micelles (1). This indicates that VA
binding correlates with the hydrophobicity of the pockets
and is consistent with the Meyer-Overton rule (48,49), which
states that anesthetic potencies correlate with partition coef-
ﬁcients between aqueous and hydrophobic phases. This rule
has been interpreted to indicate that membranes are critical
for anesthetic effects. However, these ﬁndings suggest that
hydrophobic domains within proteins are also potential an-
esthetic targets.
These ﬁndings are consistent with NMR measurements,
which demonstrated that small hydrophobic organic mole-
cules bind to hydrophobic cavities with low water occupancy
in the protein lysozyme (50). This suggests that the binding
of VAs and other small hydrophobic molecules with proteins
may arise from a set of common molecular interactions.
These ﬁndings are compelling because they indicate that
the deﬁnition of hydrophobic in the Meyer-Overton rule can
be further narrowed and quantiﬁed in protein targets to mean
pockets with a minimum degree of solvent exclusion and a
minimum number of residues that contain methyl groups.
This is an important ﬁnding, because hydrophobicity is
FIGURE 5 Effect of halothane on Ca21 Kd of CaM. Representative
titration curves of normalized ﬂuorescence intensity change for tyrosine and
phenylalanine measured in the presence and absence of 2.5 mM halothane.
The graph symbols for the control tyrosine data are open squares, control
phenylalanine data are open circles, halothane tyrosine data are 1 signs,
halothane phenylalanine data are X, control curveﬁts are solid lines, and
halothane curveﬁts are dashed lines.
TABLE 3 Ca21 titration curveﬁt parameters (mean 6 SD of ﬁts
to three titrations)
Parameter
N-domain Ca21
binding sites
C-domain Ca21
binding sites
Halothane (mM) 0 2.5 0 2.5
Kd (mM)*
y 7.4 6 0.3 5.1 6 0.1 1.50 6 0.04 0.77 6 0.04
n 1.4 6 0.2 1.7 6 0.1 1.8 6 0.1 1.5 6 0.1
*Signiﬁcant difference (p , 0.01) between N-domain Ca21 binding sites
measured in 0 and 2.5 mM halothane.
ySigniﬁcant difference (p , 0.01) between C-domain Ca21 binding sites
measured in 0 and 2.5 mM halothane.
FIGURE 4 Titrations of various concentrations of [Ca21]4-CaM with
halothane. The halothane concentrations of the injectant were between 9 and
12 mM and the [Ca21]4-CaM concentrations are 0.01, 0.05, 0.1, 0.5, and
0.69 mM in panels A–E, respectively. The upper panels show the baseline-
corrected data for the injection of halothane into [Ca21]4-CaM. The lower
panels show the normalized heat changes for each injection in calories per
mole of halothane added, which were corrected for the enthalpies of dilution
of halothane and calmodulin. The solid line overlaid on the integrated heats
is the simulated single-site-model binding isotherm calculated with param-
eters determined from a global ﬁt to all ﬁve data sets. The thermodynamic
parameters from the global curve ﬁts are tabulated along with the standard
errors of the ﬁt, as determined by the ﬁtting program.
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difﬁcult to deﬁne at the molecular level. Quantiﬁable values
that express hydrophobicity on an absolute scale, such as PW
and PWM, are easier to utilize in an approach to predict VA
binding sites based on protein structure.
We found that halothane binds to [Ca21]4-CaM, but not
apoCaM (Fig. 3), which conﬁrms our previous NMR work
(14). We determined that the halothane[Ca21]4-CaM Kd was
1.1 mM and the DH was 4.2 kcal/mol, results which are
consistent with VAs binding to HSA (34,51). However, we
found that the magnitude of DS (0.5 cal mol1 K1) was as
much as 20 times smaller than DSs measured for VA binding
interactions with HSA (51), odorant binding protein (12),
and an a-helix bundle protein (29). VA binding to proteins
has been observed to coincide with entropy gain (12,51), as
is expected for desolvation of a hydrophobic molecule and
entropy loss, which was posited to result from a reduction in
the mobility of protein side chains (29). The near-zero DS we
measured for halothane[Ca21]4-CaM binding suggests that
the entropy gain of halothane desolvation is counterbalanced
by entropy loss in the system, such as reduced mobility of
the [Ca21]4-CaM side chains. This is supported by an NMR
study of the dynamics of methyl group containing side
chains in [Ca21]4-CaM, which demonstrated that the con-
formational entropy of [Ca21]4-CaM is reduced when it
binds a peptide (52).
Structures of VA[Ca21]4-CaM complexes have yet to be
determined, so the molecular interactions and binding sites
are unknown. However, our experimental evidence indicates
that the VA binding sites in [Ca21]4-CaM are similar to those
in the known structures of VAprotein complexes. We ob-
served cross-relaxation between halothane and [Ca21]4-CaM
resonances within the range of 0–3 ppm and 6–8 ppm
(Fig. 6). This ﬁnding is consistent with NMR experiments on
halothane binding to HSA (47). Cross-relaxation indicates
that a halothane molecule is bound within ;4 A˚ of these
protein resonances. It is not possible to tell from this spec-
trum how many CaM resonances are involved, their assign-
ment, or the stoichiometry of halothane in the complex.
Additional isotope-edited measurements will reveal this
information. They are part of an ongoing effort to determine
the solution structure of halothane[Ca21]4-CaM complex,
which we will report separately. However, the frequency
ranges in which the cross-relaxation is observed informs us
about the types of 1H resonances nearby the halothane bind-
ing site(s). In general, aliphatic 1H resonances are observed
between 0 and 4 ppm, methyl 1H resonances are observed
between 0 and 3 ppm, and aromatic group 1H resonances are
observed between 6 and 8 ppm. The exact frequency of each
resonance within these ranges depends on the local envi-
ronment of the individual protons. The NOESY spectra show
that the halothane binding site(s) in [Ca21]4-CaM are
surrounded by predominantly aliphatic and to a lesser extent
aromatic 1Hs, some of which are part of residues that
inﬂuence VA binding (Table 1). This suggests that VAs bind
within ;4 A˚ of residues in the sequence of [Ca21]4-CaM,
which are similar in type to those near VA binding sites in
HSA. Thus, the molecular interactions between VAs and
[Ca21]4-CaM might be similar to those which we character-
ized in the structures of VAprotein complexes. In addition,
the afﬁnity of halothane for [Ca21]4-CaM (Fig. 4) is com-
parable to the afﬁnity of VAs for HSA (51), which indicates
that the molecular interactions are of the same magnitude.
Together, these experimental ﬁndings suggest that the mo-
lecular interactions observed in the structures of VAprotein
complexes are representative of the interactions between
halothane and [Ca21]4-CaM. Thus, it is appropriate to use
the same approach to predict VA binding sites in the struc-
tures of CaM.
BSPs in the occupancy range were found in both the
extended and compact structures of [Ca21]4-CaM (Fig. 1 B),
but not in the x-ray structure of apo-CaM (Fig. 1 B) or in 26
of 30 NMR structures deposited for apoCaM (1LKJ, (53))
(data not shown). Thus, VAs are predicted to bind to
[Ca21]4-CaM, but not apoCaM. This prediction is supported
by ITC (Fig. 3). The predicted binding site(s) are in the
hydrophobic pockets that are present in the N- and
C-domains of [Ca21]4-CaM (Fig. 2). No equivalent hydro-
phobic pockets are present in the structure of apoCaM. The
location of the predicted binding sites within these hydropho-
bic pockets is supported by the effect of halothane on the
Ca21 afﬁnity of CaM (Fig. 5). We determined the apparent
Ca21 Kd values for the N- and C-domain Ca
21 binding sites
in CaM in the absence of halothane, which agree with the
ﬁndings of others (35), and found that the Kd values decrease
in the presence of halothane. This ﬁnding is consistent with
the effect of other VAs on the Ca21 afﬁnity of the C-domain
FIGURE 6 Halothane interacts predominantly with aliphatic protons in
[Ca21]4-CaM as determined by
1HNMR. (Top) Trace of one-dimensional
1HNMR spectrum of halothane and [Ca21]4-CaM. The signal from water
(4.7 ppm) is truncated. (Bottom) Trace from NOESY of halothane and
[Ca21]4-CaM, taken along the halothane resonance at 6.3 ppm, and drawn so
the aliphatic regions in the upper and lower traces have approximately the
same scale. The signals from water (4.7 ppm) and halothane (6.3 ppm,
asterisk) are truncated. Appearance of signal in the aliphatic region (0–
4 ppm) and the aromatic region of the spectrum (6–8 ppm) indicates spatial
proximity among halothane protons and respective protein protons.
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Ca21 binding sites of CaM (37). Similar increases in the
Ca21 afﬁnity of CaM have been observed in the presence of
other drugs, peptides, and proteins, which bind to the hy-
drophobic pockets of [Ca21]4-CaM (54-57). This indicates
that VAs, like other hydrophobic drugs that increase the
Ca21 afﬁnity of CaM, bind to the hydrophobic pockets of
[Ca21]4-CaM. The computational approach did not distin-
guish whether halothane prefers to bind to the extended or
compact conformation of [Ca21]4-CaM. [Ca
21]4-CaM has
been shown to adopt a compact conformation when bound to
other small hydrophobic drugs (54,58–61). However, the
solution structure of the halothane[Ca21]4-CaM complex
will need to be determined to verify the predicted binding
sites and identify the conformation of [Ca21]4-CaM in the
complex.
This approach predicts VA binding sites within a protein
structure, but does not indicate the orientation of the VA
relative to the pocket. The location of the binding site in the
protein structure could be sufﬁcient to suggest empirical
measurements to test VA occupancy of the predicted binding
site. For example, VAs compete for fatty-acid binding sites
and quench intrinsic tryptophan emission in serum albumin
(10,21) and inhibit iron uptake, but not release in apoferritin
(62). Higher-resolution predictions can be obtained using a
docking algorithm to calculate the optimal orientation of a
particular VA molecule in the binding site. Another group
used the software AutoDock 3.0 (63) and a blind docking
procedure (64) to predict halothane-binding sites in ketoste-
roid isomerase (KSI) dimer (65). This is a rigorous method in
which binding energies are calculated for millions of unique
proteinVA geometries that are intended to sample all pos-
sible binding sites on the protein. The beneﬁts to using a
docking algorithm are that it can predict the location and
orientation of the bound VA and the binding energy can be
used to estimate the binding afﬁnity. The drawbacks are that
the calculations require force-ﬁeld parameters for the VAs
and can take considerable computational time. For compar-
ison, we used our approach to predict the VA binding sites in
KSI using the same input ﬁle (1BUQ). Both our approach
and the blind docking procedure identiﬁed halothane binding
sites in the same pockets in the KSI dimer (data not shown).
This suggests that the binding sites predicted by our ap-
proach could be used as seed locations for a focused docking
algorithm. This would provide higher-resolution predictions
and an estimate of afﬁnity, while minimizing the dimensions
of the search region and hence computation time. Thus, our
approach predicts the location(s) of VA binding within a
protein, which could be reﬁned with the implementation of a
docking algorithm.
In this work, we utilize algorithms developed to identify
and characterize ligand binding sites in proteins. The efﬁcacy
of this approach suggests that it is appropriate to apply ligand
binding concepts (i.e., binding sites, stoichiometry, and Kd)
to VA protein interactions. This does not imply that the ef-
fects of VAs on protein function are necessarily localized to
the binding site, as is thought to be the case in the com-
petitive inhibition of luciferase by VAs (13). The effects of
the VAs ligands could also delocalize over the protein struc-
ture, as suggested by a molecular dynamics simulation of
the effect of halothane on a membrane-inserted channel
protein (66).
This work shows that VA binding sites in the high
resolution structures of VAprotein complexes correlate with
descriptors of hydrophobicity (PW and PWM) that are related
to the degree to which solvent is excluded from the pocket
and the number of nearby methyl groups, respectively. Thus,
PW and PWM are consistent with the observations that VA
binding is driven, at least in part, by the hydrophobic effect
and the Meyer-Overton rule, which indicates that VAs target
hydrophobic domains. PW and PWM can be quantiﬁed
in absolute terms for high-resolution protein structures and
used to predict the site(s) of VA binding in proteins, which
could be a powerful tool in the study of molecular mech-
anisms of anesthesia. Using this approach, we predict that
VAs bind to hydrophobic pockets that are present in the
structures of [Ca21]4-CaM, but not apoCaM. This is sup-
ported with experimental ﬁndings that VAs bind to [Ca21]4-
CaM, but not apo-CaM; VAs bind near predominantly
aliphatic 1Hs in [Ca21]4-CaM, and; VAs decrease the Kd
values of Ca21 for CaM.
This study was supported in part by grant No. HL-45532 from the National
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